Non-alcoholic steatohepatitis (NASH) develops from non-alcoholic fatty liver disease
(NAFLD). Currently, around 25% of the population is estimated to have NAFLD, and 25% of …

Conspectus Understanding the interactions between nanomaterials and biological systems
plays a pivotal role in enhancing the efficacy of nanomedicine and advancing the disease …

Implementing precision medicine hinges on the integration of omics data, such as
proteomics, into the clinical decision-making process, but the quantity and diversity of …

The COVID-19 pandemic is an unprecedented global challenge, and point-of-care
diagnostic classifiers are urgently required. Here, we present a platform for ultra-high …

Alcohol-related liver disease (ALD) is a major cause of liver-related death worldwide, yet
understanding of the three key pathological features of the disease—fibrosis, inflammation …

Nano-flow liquid chromatography tandem mass spectrometry (nano-flow LC–MS/MS) is the
mainstay in proteome research because of its excellent sensitivity but often comes at the …

Parkinson's disease (PD) is a growing burden worldwide, and there is no reliable biomarker
used in clinical routines to date. Cerebrospinal fluid (CSF) is routinely collected in patients …

Neurodegenerative diseases are a growing burden, and there is an urgent need for better
biomarkers for diagnosis, prognosis, and treatment efficacy. Structural and functional brain …

The plasma proteome is the ultimate target for biomarker discovery. It stores an endless
amount of information on the pathophysiological status of a living organism, which is …

Developing a single-domain assay to identify individuals at high risk of future events is a
priority for multi-disease and mortality prevention. By training a neural network, we …